464 related articles for article (PubMed ID: 30944129)
1. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
[TBL] [Abstract][Full Text] [Related]
2. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
[TBL] [Abstract][Full Text] [Related]
3. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
Oddone F; Tanga L; Kóthy P; Holló G;
Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
[TBL] [Abstract][Full Text] [Related]
5. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.
Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
Br J Ophthalmol; 2014 Jul; 98(7):926-31. PubMed ID: 24667994
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
7. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A;
J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148
[No Abstract] [Full Text] [Related]
9. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes.
Ansari E; Chappiti S; Pavicic-Astalos J; Pinto-Bonilla JC; Riva I; Sacchi M; Saénz-Francés F
BMC Ophthalmol; 2022 Apr; 22(1):152. PubMed ID: 35366846
[TBL] [Abstract][Full Text] [Related]
10. A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy.
Holló G; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Oddone F;
Curr Med Res Opin; 2022 Jul; 38(7):1189-1201. PubMed ID: 35621005
[TBL] [Abstract][Full Text] [Related]
11. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Wong TT; Aung T; Ho CL
Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
[TBL] [Abstract][Full Text] [Related]
12. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
13. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
14. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
Chabi A; Baranak C; Lupinacci R; Herring WJ
Int J Clin Pract; 2016 Jul; 70(7):577-86. PubMed ID: 27292765
[TBL] [Abstract][Full Text] [Related]
15. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
[TBL] [Abstract][Full Text] [Related]
16. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
Hoy SM
Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
18. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
[TBL] [Abstract][Full Text] [Related]
19. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
[TBL] [Abstract][Full Text] [Related]
20. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]